A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes

Condition:   Atrial Fibrillation Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Warfarin Sponsors:   Bayer;   Janssen Research and Development LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials